PolyPid Ltd. — Regulatory Filings 2020

Aug 3, 2020

6-K 1 ea124890-6k_polypidltd.htm REPORT OF FOREIGN PRIVATE ISSUER

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: August 2020

Commission File Number: 001-38428

PolyPid Ltd.

(Translation of registrant’s name into English)

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on August 3, 2020, titled “PolyPid granted Fast Track Designation from FDA for D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery.”

The first two paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Registrant’s Registration Statement on Form S-8 (Registration No. 333-239517), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit	Description
99.1	Press
Release issued by PolyPid Ltd. on August 3, 2020, titled “PolyPid granted Fast Track Designation from FDA for D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery.”

Field: Page; Sequence: 2; Options: NewSection; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| /s/
Dikla Czaczkes Akselbrad | |
| --- | --- |
| Name | Dikla
Czaczkes Akselbrad |
| Title: | Executive Vice President
and Chief Financial Officer |

2

Field: Rule-Page

Field: /Rule-Page